Angeles Secord, MD
Gynecologic Oncology · Durham, NCNPI 1073531083
Payments from drug & device makers
Across 475 payments — averaging $9734.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2.1M
- GSK$721K
- Genentech, Inc.$552K
- Clovis Oncology, Inc.$336K
- AbbVie$235K
- Immunogen, Inc.$114K
- plus $520K from 19 others
What the payments were for
- Consulting fees$54,50945%
- Speaking & faculty fees$7,9807%
- Grants$45,00037%
- Travel & lodging$8,1817%
- Food & beverage$5,1974%
- Education$1260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 91 | $2,146,981 |
| GSK | 64 | $720,763 |
| Genentech, Inc. | 35 | $552,218 |
| Clovis Oncology, Inc. | 35 | $335,536 |
| AbbVie | 34 | $234,533 |
| Immunogen, Inc. | 6 | $113,759 |
| Tesaro, Inc. | 20 | $105,886 |
| Seagen Inc. | 14 | $94,035 |
| Karyopharm Therapeutics Inc. | 19 | $51,391 |
| E.r. Squibb & Sons, L.L.C. | 2 | $48,404 |
| Astrazeneca UK Limited | 7 | $47,126 |
| Daiichi Sankyo Inc. | 87 | $45,998 |
| Myriad Genetic Laboratories, Inc. | 3 | $42,253 |
| Genmab U.S., Inc. | 5 | $39,698 |
| AstraZeneca | 20 | $33,864 |
| Histosonics, Inc. | 2 | $3,143 |
| Eisai Inc. | 15 | $3,068 |
| Medtronic | 2 | $2,590 |
| Corcept Therapeutics | 6 | $1,139 |
| Pharmaand GmbH | 1 | $896 |
| Genentech USA, Inc. | 2 | $230 |
| Pfizer | 1 | $135 |
| Roche Diagnostics Corporation | 2 | $135 |
| Johnson & Johnson | 1 | $80 |
| F. Hoffmann-la Roche AG | 1 | $60 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,623,921 in reported general payments places this provider in the 95th percentile of 52 gynecologic oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gynecologic oncology in Durham
- Laura HavrileskyDurham$176K
- William LoweryDurham$67K
- Andrew BerchuckDurham$12K
- Haley MossDurham$2K
- Janelle FauciCharlotte$2.7M
- Linda van leChapel Hill$1.4M
- Timothy VanderkwaakSylva$908K
- Joshua TrinidadWinston Salem$803K
- Victoria Bae-JumpChapel Hill$791K
- Robert NaumannCharlotte$575K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.